Biotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel, and Biogen

Wednesday, March 1, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 1, 2017 /PRNewswire/ --

Four Biotech equities have been lined up by today, and

they are Immunomedics Inc. (NASDAQ: IMMU), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Vericel Corp. (NASDAQ: VCEL), and Biogen Inc. (NASDAQ: BIIB). These firms are part of the Healthcare sector, which extended its declines in afternoon trade on
Tuesday, February 28
th, 2017, with the NYSE Health Care Index falling about 0.5%, while shares of health care companies in the S&P 500 were down more than 0.4% as a group. You can access our complimentary research reports on these stocks now at:


Morris Plains, New Jersey headquartered Immunomedics Inc.'s shares dropped 2.34%, closing Tuesday's trading session at $5.00. The stock recorded a trading volume of 2.06 million shares. Shares of the Company have advanced 7.53% in the last month, 44.09% in the previous three months, and 36.24% on an YTD basis. The stock is trading 17.51% above its 50-day moving average and 52.58% above its 200-day moving average. Additionally, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have a Relative Strength Index (RSI) of 57.86.

On February 27th, 2017, Immunomedics announced that it has issued an open letter to Immunomedics' stockholders and recommended that stockholders vote "FOR" each of the Company's director nominees -- Jason Aryeh, Dr. Geoffrey Cox, Robert Forrester, Dr. David M. Goldenberg, Brian A. Markison, Bob Oliver and Cynthia L. Sullivan -- on the WHITE proxy card in connection with the Company's 2016 Annual Meeting of Stockholders being held on March 03rd, 2017. Visit us today and download your complete report on IMMU for free at:

Peregrine Pharma

On Tuesday, shares in Tustin, California headquartered Peregrine Pharmaceuticals Inc. recorded a trading volume of 6.76 million shares, which was above their three months average volume of 3.11 million shares. The stock edged 6.14% higher, ending the day at $0.61. The Company's shares have surged 108.62% in the last month, 95.16% over the previous three months, and 95.16% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 76.90% and 64.78%, respectively. Furthermore, shares of Peregrine Pharma, which researches and develops monoclonal antibodies for the treatment of cancer in the US, have an RSI of 78.56.

On February 09th, 2017, Peregrine Pharmaceuticals announced the publication of positive proof-of-concept data for a novel exosome-based cancer detection platform. Results of the study, conducted at University of Texas Southwestern Medical Center, showed researchers were able to distinguish between healthy subjects and patients with ovarian tumors based on the levels of exosomes containing phosphatidylserine (PS) found in their plasma. Furthermore, analysis of the PS-positive exosome levels allowed researchers to distinguish between malignant and benign tumors. The complimentary research report on PPHM can be accessed at:


Cambridge, Massachusetts headquartered Vericel Corp.'s stock finished the day 1.69% higher at $3.00 with a total trading volume of 219,711 shares. The Company's shares have gained 15.38% in the last one month and 17.65% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 3.66% and 18.35%, respectively. Additionally, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, have an RSI of 57.20.

On February 21st, 2017, Vericel announced that the US Food and Drug Administration has designated the investigation of ixmyelocel-T for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Track Development Program. Register for free on and download the PDF research report on VCEL at:


Shares in Cambridge, Massachusetts headquartered Biogen Inc. ended yesterday's session 0.87% lower at $288.60. The stock recorded a trading volume of 1.25 million shares. The Company's shares have advanced 3.73% in the last one month and 1.77% on an YTD basis. The stock is trading 2.00% and 0.67% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide, have an RSI of 57.01.

On February 01st, 2017, Biogen announced the completion of the separation of its global hemophilia business. The new Company, known as Bioverativ, is an independent, publicly traded global biotechnology company focused on hemophilia and other rare blood disorders.

On February 07th, 2017, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'. Get free access to your research report on BIIB at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store